Epilepsy patients looking for more permanent care identified a rare treatable disease
Credit: ArtemiLifeANS is a rare disorder that can cause debilitating pain. Our research has identified the brain activity abnormalities in people who respond to dopamine replacement therapy said Willem Donders a doctoral candidate in bioCHA an International Union Against Tuberculosis and Lung Disease (ITBAT) research center. The neuroscientist and his colleagues had already demonstrated that acute (or abnormal) DA3A receptor activation can be used to erase or interrupt a type of dopamine-signaling pathway in the brain. However the present study is the first to show an inevitable delay between activation and the occurrence of this neuronal dysregulation at Nektar neuroeconomies-specifically the Pavlovalian pain circuitry.
Dopamine therapy for chronic pain can restore independence and extended life in approximately half of those suffering from it. However it is often painful with prolonged-release dopamine therapy or can cause new-onset addiction. Existing treatments develop with a limited duration. Furthermore the addictive effects are higher than those of dopamine therapy. It was thought that chronic dopamine action and dysregulation are progressively enhanced as the disease progresses. Thus a functional mechanism for progressively restoring normal dopamine system function with dopamine replacement therapy appears to be our best hope for the fight against chronic pain.
Willem Donders PhD ENT doctor and researcher NEEL Medical Center Department of Emergency Medicine Frejus M. Heidelberg Landstuhl Regional Hospital Amsterdam The Netherlands.
To address this elusive question Willem Donders Withder Professor at the Department of Emergency Medicine Leiden University Medical Center Leiden The Netherlands and his colleagues explained that These are the conclusions of our research. For the foreseeable future future a silencing of the DA3A receptor may be of value provided that disruption continues to occur naturally over the long-term.
The findings are published in NeuroThesis.